Last reviewed · How we verify

Roflumilast Cream 0.3%

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

Roflumilast Cream 0.3% is a Phosphodiesterase-4 inhibitor Small molecule drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD). Also known as: Zoryve, ARQ-151.

Roflumilast is a phosphodiesterase-4 inhibitor, which reduces inflammation by inhibiting the production of pro-inflammatory cytokines.

Roflumilast is a phosphodiesterase-4 inhibitor, which reduces inflammation by inhibiting the production of pro-inflammatory cytokines. Used for Chronic obstructive pulmonary disease (COPD).

At a glance

Generic nameRoflumilast Cream 0.3%
Also known asZoryve, ARQ-151
SponsorHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Drug classPhosphodiesterase-4 inhibitor
TargetPhosphodiesterase-4
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

By inhibiting phosphodiesterase-4, roflumilast decreases the levels of cyclic adenosine monophosphate (cAMP) in inflammatory cells, leading to a reduction in the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 beta (IL-1β). This results in decreased inflammation and improved symptoms in patients with chronic obstructive pulmonary disease (COPD).

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Roflumilast Cream 0.3%

What is Roflumilast Cream 0.3%?

Roflumilast Cream 0.3% is a Phosphodiesterase-4 inhibitor drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., indicated for Chronic obstructive pulmonary disease (COPD).

How does Roflumilast Cream 0.3% work?

Roflumilast is a phosphodiesterase-4 inhibitor, which reduces inflammation by inhibiting the production of pro-inflammatory cytokines.

What is Roflumilast Cream 0.3% used for?

Roflumilast Cream 0.3% is indicated for Chronic obstructive pulmonary disease (COPD).

Who makes Roflumilast Cream 0.3%?

Roflumilast Cream 0.3% is developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (see full Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. pipeline at /company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd).

Is Roflumilast Cream 0.3% also known as anything else?

Roflumilast Cream 0.3% is also known as Zoryve, ARQ-151.

What drug class is Roflumilast Cream 0.3% in?

Roflumilast Cream 0.3% belongs to the Phosphodiesterase-4 inhibitor class. See all Phosphodiesterase-4 inhibitor drugs at /class/phosphodiesterase-4-inhibitor.

What development phase is Roflumilast Cream 0.3% in?

Roflumilast Cream 0.3% is in Phase 3.

What are the side effects of Roflumilast Cream 0.3%?

Common side effects of Roflumilast Cream 0.3% include Diarrhea, Nausea, Headache, Dizziness, Fatigue.

What does Roflumilast Cream 0.3% target?

Roflumilast Cream 0.3% targets Phosphodiesterase-4 and is a Phosphodiesterase-4 inhibitor.

Related